Paradigm Biopharmaceuticals has selected Advanced Clinical as the clinical research organisation (CRO) to support its pivotal ...

Paradigm Biopharmaceuticals continues to edge closer towards starting the pivotal phase III trial for its knee osteoarthritis ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

PhaseV has formed a strategic collaboration with Alimentiv for supporting the design and execution of adaptive clinical ...

Annovis Bio has commenced the treatment of subjects in a Phase III clinical trial of buntanetap in treating early Alzheimer's ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard-of-care in patients with ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...